Arbutus Biopharma (ABUS) Accounts Payables (2010 - 2026)

Arbutus Biopharma has disclosed Accounts Payables across 17 years of filings, most recently posting $4.5 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $4.5 million, down 63.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 million (down 63.05% YoY), and the FY2025 annual result was $5.5 million, down 27.83% from the prior year.
• Accounts Payables came in at $4.5 million for Q1 2026 at Arbutus Biopharma, down from $5.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $16.0 million in Q4 2022 to a low of $4.5 million in Q1 2026.
• The 5-year median for Accounts Payables is $8.8 million (2023), against an average of $9.0 million.
• Across the five-year window, Accounts Payables soared 49.35% in 2022 and slumped 63.05% in 2026, its largest moves.
• Arbutus Biopharma's Accounts Payables stood at $16.0 million in 2022, then tumbled by 35.92% to $10.3 million in 2023, then decreased by 26.36% to $7.6 million in 2024, then decreased by 27.83% to $5.5 million in 2025, then fell by 18.04% to $4.5 million in 2026.
• The last three Accounts Payables figures came in at $4.5 million (Q1 2026), $5.5 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.